![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Seventeen patients with head and neck recurrent carcinoma underwent 125I seed implantation under CT or ultrasound guidance. The actuarial D90 of the 125I seeds implanted was 90–160 Gy (median, 126 Gy). Median follow-up was 10 months (range, 3–48 months). The median local control time was 16 months; the 1- and 2-year local control rates were 66.5% and 49.9%, respectively. The 1- and 2-year survival rates were 51.3% and 38.5%, respectively (median, 16 months). None of the patients experienced grade 4 toxicity. 125I seed implantation was a feasible and effective salvage treatment for patients with recurrent head and neck cancers.
ACKNOWLEDGMENT
We thank Dr. Wei-Juan Jiang for manuscript assistance, Dr. Jin-Na Li, and Su-Qing Tian for their help in figure preparation. This work was supported by the Capital Medical Development Grant of Beijing (2009–2024).
| ABBREVIATIONS | ||
| 125I | = | iodine-125 |
| LDR | = | low-dose rate |
| HDR | = | high-dose rate |
| MPD | = | matched peripheral dose |
| TPS | = | treatment planning system |
| EBRT | = | external beam radiotherapy |
| GTV | = | gross tumor volume |
| PTV | = | planning target volume |
| CR | = | complete response |
| PR | = | partial response |
| SD | = | stable disease |
| PD | = | progressive disease |
| TTP | = | time to progression |
| OS | = | overall survival |